109th CONGRESS
1st Session
H. R. 2877
To provide for the expansion and intensification of efforts for prevention,
education, and research activities with respect to Lyme and other tick-borne
diseases, including the establishment of a Tick-Borne Diseases Advisory Committee.
IN THE HOUSE OF REPRESENTATIVES
June 14, 2005
Mr. SMITH of New Jersey (for himself, Mr. GILCHREST, and Mr. PLATTS) introduced
the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To provide for the expansion and intensification of efforts for prevention,
education, and research activities with respect to Lyme and other tick-borne
diseases, including the establishment of a Tick-Borne Diseases Advisory Committee.
Be it enacted by the Senate and House of Representatives of the United
States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the `Act for Lyme Education and Research and Tick-Borne
Diseases' or the `ALERT Act'.
SEC. 2. FINDINGS.
The Congress finds as follows:
(1) The United States alone has 82 species of ticks causing at least 10
major diseases, which are Lyme disease, anaplasmosis, human monocytic ehrlichosis,
babesiosis, tick paralysis, relapsing fever, tularemia, Rocky Mountain spotted
fever, Colorado tick fever, and southern tick-associated rash illness (STARI)
(also known as Masters' disease). New tick species continue to be classified,
and new diseases continue to emerge.
(2) Lyme disease is the most prevalent vector-borne disease in the United
States today.
(3) According to the Centers for Disease Control and Prevention, only 10
percent of cases that meet its surveillance criteria are reported; thus,
an estimated 200,000 to 240,000 new cases occur each year.
(4) Tests to detect serum antibodies for Lyme disease can yield a high number
of false-positive and false-negative results. False-negative results may
delay diagnosis and treatment, which may lead to chronic, more debilitating,
persistent and costly disease.
(5) The diagnosis and treatment picture of Lyme disease and other tick-borne
diseases can be complicated because more than one tick-borne disease can
be acquired by the bite of the same tick.
(6) If it is not diagnosed and treated early, Lyme disease can lead to chronic
illness and can affect every system in the body, including the central nervous
system. Diagnosis is complicated because Lyme disease can mimic diseases
such as meningitis, multiple sclerosis, brain tumor, Alzheimer's disease,
Parkinson's disease, ALS, and psychiatric illness.
(7) According to a study by the National Institutes of Health, patients
with persistent Lyme disease suffer physical disability equivalent to that
of congestive heart failure, severe pain equivalent to post-operative pain,
and profound fatigue similar to multiple sclerosis.
SEC. 3. GOALS.
(a) Five-Year Plan- The Secretary of Health and Human Services, acting as
appropriate through the Director of the Agency for Healthcare Research and
Quality, the Director of the Centers for Disease Control and Prevention, and
the Director of the National Institutes of Health, shall establish a plan
that, for the five fiscal years following the date of the enactment of this
Act, provides for activities to be carried out during such fiscal years toward
achieving the goals described in paragraphs (1) through (4) of subsection
(b). The plan shall, as appropriate to such goals, provide for the coordination
of programs and activities regarding Lyme disease and other tick-borne diseases
that are conducted or supported by the Federal Government.
(1) FIRST GOAL: DIAGNOSTIC TEST- The first goal under subsection (a) shall
be--
(A) to develop a sensitive and definitive test for the diagnosis of Lyme
disease capable of distinguishing active infection from past infection;
(B) to improve efficient utilization of diagnostic testing currently available
to account for the multiple clinical manifestations of both acute and
chronic Lyme disease; and
(C) to provide for the rapid evaluation and adoption of emerging test
methods.
(2) SECOND GOAL: SURVEILLANCE AND REPORTING OF LYME DISEASE AND OTHER TICK-BORNE
DISEASES- The second goal under subsection (a) shall be--
(A) to accurately determine the prevalence of Lyme disease and other tick-borne
diseases in the United States;
(B) to evaluate the feasibility of developing a reporting system for collecting
data on physician-diagnosed cases that do not meet the surveillance criteria
of the Centers for Disease Control and Prevention in order to more accurately
gauge disease outbreaks and incidence; and
(C) to evaluate the feasibility of creating a national uniform reporting
system to include mandatory reporting by laboratories in each State.
(3) THIRD GOAL: PREVENTION OF LYME DISEASE AND OTHER TICK-BORNE DISEASES
AND COMPLICATIONS DUE TO DELAYED DIAGNOSIS AND TREATMENT- The third goal
under subsection (a) shall be--
(A) for the Director of the Agency for Healthcare Research and Quality,
in coordination with the Director of the Centers for Disease Control and
Prevention and the Director of the National Institutes of Health, to provide
and promote access to a comprehensive, up-to-date clearinghouse of peer-reviewed
information on Lyme and other tick-borne diseases;
(B) to provide for public education by expanding the Community Based Education
Programs of the Centers for Disease Control and Prevention to include
expansion of information access points available to the public;
(C) to create a physician education program that includes the full spectrum
of scientific research on Lyme and other tick-borne diseases; and
(D) for the Secretary to sponsor scientific conferences on Lyme and other
tick-borne diseases, including reporting and consideration of the full
spectrum of clinically-based knowledge, with the first of such conferences
held within 24 months after the date of the enactment of this Act and
with further conferences held as determined appropriate by the Secretary.
(4) FOURTH GOAL: CLINICAL OUTCOMES RESEARCH- The fourth goal under subsection
(a) shall be--
(A) to establish epidemiological research goals to determine the long
term course of illness for Lyme disease; and
(B) to establish treatment outcomes research goals to determine the effectiveness
of different treatment modalities.
SEC. 4. STUDY BY INSTITUTE OF MEDICINE.
(a) In General- Not later than 90 days after the date of the enactment of
this Act, the Secretary shall request the Institute of Medicine, National
Academies of Sciences, to enter into an agreement with the Secretary for the
conduct of a study of chronic Lyme disease. Such study shall include a systematic
assessment of empirical evidence of treating physicians, as well as published
peer-reviewed data, and shall include recommendations for addressing research
gaps in diagnosis and treatment of chronic Lyme disease and an assessment
of treatment guidelines, such as those of the Infectious Diseases Society
of America and those of the International Lyme and Associated Diseases Society,
and their utilization.
(b) Report- The Secretary shall ensure that, not later than one year after
the Secretary enters into the agreement under subsection (a), a report providing
the results of the study under such subsection is submitted to the Secretary
and the Tick-Borne Diseases Advisory Committee under section 6.
SEC. 5. INCREASED FUNDING FOR RESEARCH AND EDUCATION.
(a) In General- For the purpose of providing for research and educational
activities for Lyme and other tick-borne diseases, and for carrying out efforts
to prevent Lyme and other tick-borne diseases, there is authorized to be appropriated
$20,000,000 for each of the fiscal years 2006 through 2010. Such authorization
is in addition to other authorizations of appropriations that are available
for such purpose.
(b) Study- Of the amounts appropriated under subsection (a), the Secretary
shall reserve not more than $500,000 for conducting the study under section
4.
SEC. 6. ESTABLISHMENT OF TICK-BORNE DISEASES ADVISORY COMMITTEE.
(a) Establishment- Not later than 180 days after the date of the enactment
of this Act, the Secretary shall establish within the Office of the Secretary
an advisory committee to be known as the Tick-Borne Diseases Advisory Committee
(referred to in this section as the `Committee').
(b) Duties- The Committee shall advise the Secretary and the Assistant Secretary
for Health regarding the manner in which such officials can--
(1) ensure interagency coordination and communication and minimize overlap
regarding efforts to address tick-borne diseases;
(2) identify opportunities to coordinate efforts with other Federal agencies
and private organizations addressing such diseases;
(3) ensure interagency coordination and communication with constituency
groups;
(4) ensure that a broad spectrum of scientific viewpoints are represented
in public health policy decisions and that information disseminated to the
public and physicians is balanced; and
(5) advise relevant Federal agencies on priorities.
(A) IN GENERAL- From among individuals who are not officers or employees
of the Federal Government, the Secretary shall appoint to the Committee,
as voting members, an equal number of individuals from each of the groups
described in clauses (i) through (v), as follows:
(i) Scientific community members representing the broad spectrum of
viewpoints held within the scientific community, such as members of
the International Lyme and Associated Diseases Society.
(ii) Representatives of tick-borne disease voluntary organizations.
(iii) Health care providers who are full-time practicing physicians
providing care for acute and chronic tick-borne diseases.
(iv) Patient representatives who are individuals who have been diagnosed
with tick-borne diseases or who have had an immediate family member
diagnosed with such a disease.
(v) Representatives of State and local health departments and national
organizations that represent State and local health professionals.
(B) CERTAIN REQUIREMENT- In appointing members under subparagraph (A),
the Secretary shall ensure that such members, as a group, represent a
diversity of scientific perspectives relevant to the duties of the Committee.
(2) EX OFFICIO MEMBERS- The Secretary shall designate the Assistant Secretary
for Health as a nonvoting, ex officio member of the Committee. In addition,
the Secretary shall designate, as nonvoting members of the Committee, representatives
from each of the following Federal agencies:
(A) The Agency for Healthcare Research and Quality.
(B) The National Institutes of Health.
(C) The Centers for Disease Control and Prevention.
(D) The Food and Drug Administration.
(E) The Office of the Assistant Secretary for Health.
(F) Such additional Federal agencies as the Secretary determines to be
appropriate.
(3) CHAIR- The members of the Committee appointed under paragraph (1) shall
select an individual from among such members to serve as the chair of the
Committee. The term for serving as the chair shall be two years.
(4) TERM OF APPOINTMENT- The term of service for each member of the Committee,
other than the Assistant Secretary for Health, shall be four years.
(5) VACANCY- A vacancy in the membership of the Committee shall be filled
in the same manner as the original appointment. Any member appointed to
fill a vacancy for an unexpired term shall be appointed for the remainder
of that term. Members may serve after the expiration of their terms until
their successors have taken office.
(d) Meetings- The Committee shall hold public meetings, except as otherwise
determined by the Secretary, giving notice to the public of such, and meet
at least twice a year with additional meetings subject to the call of the
Chair. Agenda items may be added at the request of members of the Committee,
including the Chairs. Meetings shall be conducted, and records of the proceedings
shall be maintained, as required by applicable law and by regulations of the
Secretary.
(e) Authorization of Appropriations- For the purpose of carrying out this
section, there is authorized to be appropriated $250,000 for each of the fiscal
years 2006 and 2007. Amounts appropriated under the preceding sentence shall
be used for the expenses and per diem costs incurred by the Committee under
this section in accordance with the Federal Advisory Committee Act, except
that no voting member of the Committee shall be a permanent salaried employee.
SEC. 7. REPORTS.
(a) In General- Not later than 24 months after the date of the enactment of
this Act, and annually thereafter, the Secretary shall submit to the Congress
a report on the activities carried out under this Act.
(b) Content- Reports under subsection (a) shall describe--
(1) progress in the development of accurate diagnostic tools and treatment
modalities and their use in clinical settings;
(2) the promotion of public awareness and physician education initiatives
to improve the knowledge of health care providers and the public regarding
clinical and surveillance practices for Lyme disease and other tick-borne
diseases; and
(3) other significant activities relating to surveillance, diagnosis, treatment,
or prevention of Lyme and other tick-borne diseases.
SEC. 8. DEFINITION.
For purposes of this Act, the `Secretary' means the Secretary of Health and
Human Services.
END